MRFF – CTA Initiative – 2025 Clinical Trials Activity Grant Opportunity

Purpose and Program Overview

The Medical Research Future Fund (MRFF) – Clinical Trials Activity Grant – 2025 Clinical Trials Activity Grant Opportunity (GO7923) is a federal funding scheme designed to expand clinical trials activity across Australia. Administered by the National Health and Medical Research Council (NHMRC) on behalf of the Australian Government Department of Health, Disability and Ageing, the program aims to improve the evidence base for health interventions and accelerate the translation of scientific research into routine clinical practice. The initiative focuses specifically on trials that address national health priorities while improving patient, health system, and population outcomes.

The opportunity manages a total active funding pool of up to $61,000,000 AUD for this round. This program serves a vital structural role in supporting the Australian biotechnology, pharmaceutical, and medical technology sectors. By funding large-scale clinical investigations, the program drives commercial innovation, assists medical businesses in validating new health technologies, and ensures Australian patients gain early access to life-changing healthcare interventions and therapies.

Key Grant Details

• Grant Amount: Individual project allocations range from $0 to $5,000,000 AUD, scaling according to the trial scope and clinical requirements.
• Application Dates: Submissions opened on September 24, 2025. The minimum data deadline occurred on March 4, 2026, and final applications closed on April 1, 2026.
• Eligible Industries: Healthcare services, biotechnology, medical technology development, pharmaceuticals, and higher education research.
• Required Co-contributions: Matching institutional co-funding is not explicitly mandated under the core program rules.
• Location Applicability: Nationwide applicability across all Australian states and territories.

Priority Sectors

The grant opportunity explicitly establishes four distinct priority sectors for capital distribution:

• Rare Cancers and Rare Diseases: Targeted funding for pilot feasibility studies and full-scale clinical trials addressing rare malignancies and rare medical conditions.
• Unmet Clinical Needs: Research into serious health conditions where current treatment options are either limited, ineffective, or unavailable.
• Health Technology Assessment (HTA) Gaps: Clinical trials focused on gathering data to resolve specific evidence gaps, thereby supporting Australian HTA approval systems.
• Prevention and Early Intervention: Initiatives testing preventative measures designed to limit the initial onset or clinical progression of chronic diseases.

Funding Scope

The financial architecture for this grant round breaks down the total $61,000,000 AUD pool across four operational streams:

• Stream 1 (Incubator): Small-scale pilot studies testing the feasibility of new trials for rare cancers, rare diseases, or unmet clinical needs. Eligible funding caps scale up to the maximum project limit.
• Stream 2 (Targeted Call for Research): Full clinical trials assessing treatments or management strategies for rare cancers, rare diseases, or unmet needs.
• Stream 3 (Targeted Call for Research): Clinical trials targeting evidence gaps to support Australian HTA systems.
• Stream 4 (Targeted Call for Research): Prevention-focused clinical trials testing early interventions designed to limit disease onset or progression.
• Project Timeline: All approved clinical trial activities and research objectives must be finalised within 7 years of executing the formal grant schedule.

Eligibility Criteria

To satisfy baseline requirements for funding under the MRFF framework, applicants must meet the following criteria:

• Institutional Registration: Submissions are exclusively restricted to entities recognised as approved MRFF Eligible Organisations.
• Portal Compliance: All application materials, investigator profiles, and project metrics must be fully processed through the electronic NHMRC Sapphire Portal.
• Compliance Framework: Applicants must adhere to standard Commonwealth grant delivery rules, clinical trial regulations, and institutional ethics approvals.
• Identification: Must operate under an approved, legally recognised corporate or institutional framework with an active Australian Business Number (ABN).

Eligible Activities and Expenses

The program permits grant capital to be directed toward distinct categories of operational trial delivery, including:

• Hiring and Personnel: Salary support for clinical trial coordinators, specialist investigators, biostatisticians, data analysts, and nursing staff.
• R&D and Technology Upgrades: Purchase of clinical trial software, data management platforms, laboratory diagnostic tools, and essential medical monitoring equipment.
• Patient and Trial Overheads: Costs linked to patient recruitment, medical examinations, drug manufacturing for trials, and multi-site clinical coordination.

Assessment Process

This program functions as a competitive, merit-based grant opportunity. Applications are currently progressing through a rigorous evaluation framework conducted by independent peer-review panels:

• Peer Review (Stage One): Review processes conducted between May and June 2026 to assess baseline trial viability and strategic parameters.
• Peer Review (Stage Two): Detailed panel assessments taking place between June and July 2026 to evaluate technical design and value configuration.
• Core Evaluation Criteria: Selection relies heavily on scientific project merit, strategic alignment with the selected stream, team capability, and overall value for money.

Recent Program Updates

The 2025 Clinical Trials Activity round introduces streamlined submission governance via the NHMRC Sapphire Portal. The round is now officially closed to new submissions, and final funding awards are anticipated to begin in December 2026 under formal embargo.

Application Tips

• Verify Sapphire Portal Status: Ensure your organisation maintains an active status as an approved MRFF Eligible Organisation prior to tracking subsequent funding rounds.
• Strictly Align with Streams: Ensure the clinical trial design matches the distinct requirements of Stream 1, 2, 3, or 4 without overlapping unrelated health themes.
• Submit Minimum Data Early: Adhere strictly to the preliminary minimum data deadlines in future rounds to prevent programmatic exclusion.
• Plan a 7-Year Budget: Construct a robust, scalable financial plan capable of sustaining multi-site clinical interventions across the full 7-year project ceiling.

Where to Get Help

Consider consulting a grant specialist like Pattens Group for a personalised eligibility assessment and expert assistance in preparing a strong, compliant and competitive application. Contact us today and get connected with Australia’s best grant specialist, boasting over 35 years of experience in the industry and a 100% success rate. For official guidelines, application details, templates, and further information, visit the official website of MRFF – CTA Initiative – 2025 Clinical Trials Activity Grant Opportunity and other associated Australian government websites.